All In Biotech

Free tool

FAERS Monitor: Lyumjev

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761109 or its brand name (Lyumjev, Insulin Lispro-Aabc). Reports on generic versions are filed under their own applications.

Reports

2,106

Serious

454

22% of reports

Hospitalization

183

Death reported

35

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • blood glucose increased566
  • infusion site pain266
  • drug ineffective224
  • injection site pain224
  • wrong technique in product usage process160
  • incorrect dose administered148
  • blood glucose decreased103
  • product dose omission issue71
  • visual impairment63
  • haemorrhage57
  • blood glucose abnormal56
  • accidental underdose55
  • infusion site erythema53
  • nausea51
  • glycosylated haemoglobin increased46

Reports by year received

View as table
YearReports
20171
20181
20192
202078
2021372
2022393
2023340
2024342
2025383
2026194

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,053 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
infusion site painSignal266210.5187.854,137
infusion site erythemaSignal5363.248.43,163
accidental underdoseSignal5538.329.51,955
blood glucose abnormalSignal5630.423.41,558
blood glucose increasedSignal56630.128.015,984
blood glucose decreasedSignal10321.517.81,990
glycosylated haemoglobin increasedSignal4618.213.7732
wrong technique in product usage processSignal1607.96.8965
injection site painSignal2247.36.41,228
incorrect dose administeredSignal1486.55.5687
haemorrhageSignal575.44.2203
visual impairmentSignal635.14.0203
product dose omission issueSignal712.41.958
drug ineffective2241.71.568
nausea510.60.510

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.